4.6 Review

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia

Journal

TRENDS IN NEUROSCIENCES
Volume 31, Issue 5, Pages 234-242

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tins.2008.02.005

Keywords

-

Categories

Funding

  1. NIMH NIH HHS [MH070560, R01 MH070560, R01 MH067999-05, MH067999, R01 MH051290, R01 MH067999, MH42261, P50 MH060450, R01 MH070560-05, MH31862, MH60450, R01 MH042261, R37 MH042261] Funding Source: Medline

Ask authors/readers for more resources

Many risk genes interact synergistically to produce schizophrenia and many neurotransmitter interactions have been implicated. We have developed a circuit-based framework for understanding gene and neurotransmitter interactions. NMDAR hypofunction has been implicated in schizophrenia because NMDAR antagonists reproduce symptoms of the disease. One action of antagonists is to reduce the excitation of fast-spiking interneurons, resulting in disinhibition of pyramidal cells. Overactive pyramidal cells, notably those in the hippocampus, can drive a hyperdopaminergic state that produces psychosis. Additional aspects of interneuron function can be understood in this framework, as follows. (i) In animal models, NMDAR antagonists reduce parvalbumin and GAD67, as found in schizophrenia. These changes produce further disinhibition and can be viewed as the aberrant response of a homeo-static system having a faulty activity sensor (the NMDAR). 00 Disinhibition decreases the power of gamma oscillation and might thereby produce negative and cognitive symptoms. (iii) Nicotine enhances the output of interneurons, and might thereby contribute to its therapeutic effect in schizophrenia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available